Airway epithelial cells mount an early response to mycobacterial infection.
air-liquid interface (ALI) 3D in vitro model
airway epithelium
host-pathogen interaction
non-tuberculous mycobacteria
tuberculosis
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
07
2023
accepted:
31
08
2023
medline:
1
11
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
Lung epithelial cells represent the first line of host defence against foreign inhaled components, including respiratory pathogens. Their responses to these exposures may direct subsequent immune activation to these pathogens. The epithelial response to mycobacterial infections is not well characterized and may provide clues to why some mycobacterial infections are cleared, while others are persistent and pathogenic. We have utilized an air-liquid interface model of human primary bronchial epithelial cells (ALI-PBEC) to investigate the epithelial response to infection with a variety of mycobacteria:
Identifiants
pubmed: 37822359
doi: 10.3389/fcimb.2023.1253037
pmc: PMC10562574
doi:
Substances chimiques
Cytokines
0
Chemokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253037Informations de copyright
Copyright © 2023 Barclay, Ninaber, van Veen, Hiemstra, Ottenhoff, van der Does and Joosten.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mucosal Immunol. 2018 Jan;11(1):21-34
pubmed: 28812547
Nature. 2013 Oct 10;502(7470):S2-3
pubmed: 24108078
PLoS One. 2012;7(11):e50052
pubmed: 23185529
Biochem Soc Trans. 2011 Aug;39(4):1023-7
pubmed: 21787341
J Innate Immun. 2020;12(1):74-89
pubmed: 30970352
mBio. 2016 Nov 22;7(6):
pubmed: 27879332
J Innate Immun. 2023 Mar 25;:
pubmed: 36966527
J Immunol. 2008 Dec 15;181(12):8521-7
pubmed: 19050270
Nat Rev Cancer. 2010 Aug;10(8):561-74
pubmed: 20651737
Toxicol Sci. 2018 Jul 1;164(1):21-30
pubmed: 29534242
Toxicol In Vitro. 2018 Mar;47:137-146
pubmed: 29155131
J Clin Invest. 2014 Mar;124(3):1268-82
pubmed: 24509076
Sci Rep. 2019 Sep 10;9(1):12937
pubmed: 31506515
Infect Immun. 1999 Feb;67(2):653-8
pubmed: 9916072
FEMS Immunol Med Microbiol. 2000 Sep;29(1):27-33
pubmed: 10967257
PLoS Pathog. 2017 Sep 1;13(9):e1006577
pubmed: 28863187
Am J Respir Cell Mol Biol. 2018 Feb;58(2):241-252
pubmed: 28915071
Infect Immun. 2005 Aug;73(8):4505-11
pubmed: 16040961
Eur Respir J. 2019 Nov 7;54(5):
pubmed: 31515398
J Exp Med. 1992 Apr 1;175(4):973-82
pubmed: 1552290
Infect Immun. 2002 Apr;70(4):1684-93
pubmed: 11895930
Thorax. 2022 Apr;77(4):408-416
pubmed: 35017314
Immunol Rev. 2021 May;301(1):122-144
pubmed: 33709421
Mol Microbiol. 2022 Mar;117(3):682-692
pubmed: 34605588
J Clin Invest. 2020 Jun 1;130(6):3098-3112
pubmed: 32134742
Mucosal Immunol. 2019 Mar;12(2):555-564
pubmed: 30446726
Science. 1999 Oct 15;286(5439):525-8
pubmed: 10521347
Infect Immun. 1996 Apr;64(4):1400-6
pubmed: 8606107
Exp Eye Res. 2022 Oct;223:109198
pubmed: 35921962
Semin Cell Dev Biol. 2015 Mar;39:106-14
pubmed: 24718315
Curr Opin Immunol. 2008 Jun;20(3):288-94
pubmed: 18511250
Science. 2010 Jan 22;327(5964):466-9
pubmed: 20007864
Nat Med. 2019 Feb;25(2):255-262
pubmed: 30664782
Lancet. 1995 Nov 18;346(8986):1339-45
pubmed: 7475776
Immunobiology. 1988 Sep;177(4-5):363-70
pubmed: 2848761
Front Cell Infect Microbiol. 2022 Jun 24;12:872361
pubmed: 35811670
Cell Rep Med. 2021 Jan 19;2(1):100185
pubmed: 33521699
Expert Rev Vaccines. 2019 Dec;18(12):1271-1284
pubmed: 31876199
Front Physiol. 2021 Nov 26;12:749077
pubmed: 34899381